Table 1. Patients with Incident Lung/Bronchus, Breast, Colorectal and Prostate Cancers, Maine Cancer Registry, 2017-2021 (n=20,108)

Table 1. Patients with Incident Lung/Bronchus, Breast, Colorectal and Prostate Cancers, Maine Cancer Registry, 2017-2021 (n=20,108)
Characteristic Overall
N = 20,1081		 Breast
N = 7,2631		 Colorectal
N = 3,0611		 Lung/Bronchus
N = 5,0941		 Prostate
N = 4,6901
Age at diagnosis NA (NA) NA (NA) NA (NA) NA (NA) NA (NA)
    Missing 20,108 7,263 3,061 5,094 4,690
Age Group (at dx)




    Unknown 20,108 (100%) 7,263 (100%) 3,061 (100%) 5,094 (100%) 4,690 (100%)
Sex




    Female 11,366 (57%) 7,263 (100%) 1,550 (51%) 2,553 (50%) 0 (0%)
    Male 8,742 (43%) 0 (0%) 1,511 (49%) 2,541 (50%) 4,690 (100%)
White




    White 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Other 73 (0.4%) 33 (0.5%) 14 (0.5%) 11 (0.2%) 15 (0.3%)
    Unknown 20,035 (100%) 7,230 (100%) 3,047 (100%) 5,083 (100%) 4,675 (100%)
Insurance




    Commercial 6,549 (33%) 3,214 (45%) 1,010 (34%) 927 (19%) 1,398 (30%)
    Medicare 9,102 (46%) 2,821 (39%) 1,294 (43%) 2,448 (49%) 2,539 (55%)
    Medicaid 1,268 (6.4%) 419 (5.8%) 236 (7.9%) 469 (9.4%) 144 (3.1%)
    Medicare/Medicaid 1,871 (9.4%) 496 (6.9%) 309 (10%) 806 (16%) 260 (5.6%)
    Veterans/public health service 788 (4.0%) 145 (2.0%) 103 (3.4%) 280 (5.6%) 260 (5.6%)
    Not insured 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Unknown 261 (1.3%) 91 (1.3%) 47 (1.6%) 76 (1.5%) 47 (1.0%)
    Missing 269 77 62 88 42
Rural Classification




    Urban 10,017 (50%) 3,759 (52%) 1,464 (48%) 2,564 (50%) 2,230 (48%)
    Large rural 3,461 (17%) 1,274 (18%) 552 (18%) 823 (16%) 812 (17%)
    Small rural 2,531 (13%) 823 (11%) 432 (14%) 678 (13%) 598 (13%)
    Isolated rural 4,099 (20%) 1,407 (19%) 613 (20%) 1,029 (20%) 1,050 (22%)
ADI Quintile




    ADI_Q1 3,297 (16%) 1,322 (18%) 456 (15%) 673 (13%) 846 (18%)
    ADI_Q2 4,106 (20%) 1,659 (23%) 602 (20%) 918 (18%) 927 (20%)
    ADI_Q3 4,300 (21%) 1,502 (21%) 676 (22%) 1,125 (22%) 997 (21%)
    ADI_Q4 4,661 (23%) 1,528 (21%) 748 (24%) 1,290 (25%) 1,095 (23%)
    ADI_Q5 3,398 (17%) 1,121 (15%) 531 (17%) 1,018 (20%) 728 (16%)
    Unknown 346 (1.7%) 131 (1.8%) 48 (1.6%) 70 (1.4%) 97 (2.1%)
Stage




    In situ 1,319 (6.6%) 1,216 (17%) 89 (2.9%) 14 (0.3%) 0 (0%)
    Localized 10,523 (52%) 4,322 (60%) 1,187 (39%) 1,504 (30%) 3,510 (75%)
    Regional 4,733 (24%) 1,439 (20%) 1,258 (41%) 1,366 (27%) 670 (14%)
    Distant 3,533 (18%) 286 (3.9%) 527 (17%) 2,210 (43%) 510 (11%)
Year of dx




    2017 3,859 (19%) 1,414 (19%) 606 (20%) 978 (19%) 861 (18%)
    2018 3,811 (19%) 1,354 (19%) 581 (19%) 979 (19%) 897 (19%)
    2019 4,144 (21%) 1,480 (20%) 641 (21%) 1,046 (21%) 977 (21%)
    2020 3,901 (19%) 1,356 (19%) 589 (19%) 1,070 (21%) 886 (19%)
    2021 4,393 (22%) 1,659 (23%) 644 (21%) 1,021 (20%) 1,069 (23%)
COVID Epoch of Year Diagnosed




    Pre-COVID 11,814 (59%) 4,248 (58%) 1,828 (60%) 3,003 (59%) 2,735 (58%)
    Early COVID (2020) 3,901 (19%) 1,356 (19%) 589 (19%) 1,070 (21%) 886 (19%)
    COVID (2021) 4,393 (22%) 1,659 (23%) 644 (21%) 1,021 (20%) 1,069 (23%)
1 Median (SD); n (%)

Table 2: Cancer Treatment for Patients with Localized/Regional Stage Breast Cancer

Characteristic Urban
N = 2,9471		 Large rural
N = 1,0401		 Small rural
N = 6521		 Isolated rural
N = 1,1221		 p-value2
Surgical resection 2,857 (97%) 1,013 (97%) 625 (96%) 1,095 (98%) 0.2
Chemotherapy 892 (30%) 339 (33%) 193 (30%) 294 (27%) 0.021
Radiation 324 (59%) 115 (62%) 69 (58%) 123 (53%) 0.3
Hormone therapy 2,157 (76%) 800 (79%) 453 (76%) 824 (77%) 0.2
Immunotherapy 287 (9.8%) 127 (12%) 47 (7.4%) 94 (8.4%) 0.003
Time to treatment (days) 37 (30) 35 (26) 34 (31) 36 (31) 0.022
1 n (%); Median (IQR)
2 Pearson’s Chi-squared test; Kruskal-Wallis rank sum test
Characteristic
Localized/Regional
Distant
Urban
N = 2,9471		 Large rural
N = 1,0401		 Small rural
N = 6521		 Isolated rural
N = 1,1221		 p-value2 Urban
N = 1531		 Large rural
N = 331		 Small rural
N = 391		 Isolated rural
N = 611		 p-value3
Surgical resection 2,857 (97%) 1,013 (97%) 625 (96%) 1,095 (98%) 0.2 18 (12%) 7 (21%) 7 (18%) 12 (20%) 0.3
Chemotherapy 892 (30%) 339 (33%) 193 (30%) 294 (27%) 0.021 114 (75%) 24 (73%) 22 (63%) 44 (72%) 0.6
Radiation 324 (59%) 115 (62%) 69 (58%) 123 (53%) 0.3 8 (30%) 1 (20%) 2 (33%) 5 (42%) 0.8
Hormone therapy 2,157 (76%) 800 (79%) 453 (76%) 824 (77%) 0.2 96 (64%) 16 (50%) 25 (71%) 39 (67%) 0.3
Immunotherapy 287 (9.8%) 127 (12%) 47 (7.4%) 94 (8.4%) 0.003 44 (29%) 16 (48%) 6 (16%) 8 (13%) <0.001
Time to treatment (days) 37 (30) 35 (26) 34 (31) 36 (31) 0.022 15 (26) 16 (35) 14 (35) 17 (34) 0.5
1 n (%); Median (IQR)
2 Pearson’s Chi-squared test; Kruskal-Wallis rank sum test
3 Pearson’s Chi-squared test; Fisher’s exact test; Kruskal-Wallis rank sum test

Table 3: Cancer Treatment for Patients with Localized/Regional Stage Colorectal Cancer

Characteristic
Localized/Regional
Distant
Urban
N = 1,1851		 Large rural
N = 4531		 Small rural
N = 3381		 Isolated rural
N = 4691		 p-value2 Urban
N = 2451		 Large rural
N = 751		 Small rural
N = 781		 Isolated rural
N = 1291		 p-value3
Surgical resection 1,059 (89%) 415 (92%) 303 (90%) 409 (87%) 0.2 115 (47%) 37 (49%) 38 (49%) 57 (44%) 0.9
Chemotherapy 465 (40%) 191 (42%) 131 (40%) 193 (43%) 0.7 175 (73%) 57 (77%) 59 (76%) 92 (71%) 0.8
Radiation 47 (21%) 18 (21%) 7 (10%) 17 (17%) 0.2 6 (14%) 3 (17%) 3 (25%) 5 (18%) 0.7
Time to treatment (days) 15 (37) 15 (35) 10 (31) 20 (42) 0.012 19 (30) 25 (31) 26 (33) 26 (37) 0.076
1 n (%); Median (IQR)
2 Pearson’s Chi-squared test; Kruskal-Wallis rank sum test
3 Pearson’s Chi-squared test; Fisher’s exact test; Kruskal-Wallis rank sum test

Table 4: Cancer Treatment for Patients with Localized/Regional Stage Lung/Bronchus Cancer

Characteristic
Localized/Regional
Distant
Urban
N = 1,4501		 Large rural
N = 4931		 Small rural
N = 3721		 Isolated rural
N = 5551		 p-value2 Urban
N = 1,1031		 Large rural
N = 3301		 Small rural
N = 3041		 Isolated rural
N = 4731		 p-value2
Surgical resection 696 (48%) 265 (54%) 193 (52%) 312 (56%) 0.005 31 (2.8%) 9 (2.7%) 15 (4.9%) 16 (3.4%) 0.3
Chemotherapy 508 (35%) 190 (39%) 135 (36%) 181 (33%) 0.3 688 (63%) 205 (62%) 158 (53%) 274 (58%) 0.012
Radiation 104 (39%) 12 (17%) 33 (41%) 37 (35%) 0.003 92 (39%) 29 (55%) 21 (37%) 33 (34%) 0.089
Time to treatment (days) 40 (55) 30 (52) 41 (55) 41 (58) <0.001 21 (31) 24 (32) 19 (39) 24 (36) 0.2
1 n (%); Median (IQR)
2 Pearson’s Chi-squared test; Kruskal-Wallis rank sum test

Table 4: Cancer Treatment for Patients with Localized/Regional Stage Prostate Cancer

Characteristic
Localized/Regional
Distant
Urban
N = 2,0031		 Large rural
N = 7411		 Small rural
N = 5231		 Isolated rural
N = 9131		 p-value2 Urban
N = 2271		 Large rural
N = 711		 Small rural
N = 751		 Isolated rural
N = 1371		 p-value2
Surgical resection 690 (34%) 261 (35%) 180 (34%) 309 (34%) >0.9 18 (7.9%) 6 (8.5%) 5 (6.7%) 11 (8.0%) >0.9
Chemotherapy 8 (0.4%) 5 (0.7%) 1 (0.2%) 3 (0.3%) 0.6 42 (19%) 11 (15%) 16 (22%) 20 (15%) 0.6
Radiation 138 (38%) 44 (37%) 35 (35%) 67 (40%) 0.9 4 (9.5%) 1 (17%) 1 (14%) 4 (15%) 0.7
Hormone therapy 615 (31%) 223 (30%) 183 (35%) 286 (31%) 0.2 214 (94%) 70 (99%) 67 (89%) 127 (93%) 0.11
Time to treatment (days) 53 (71) 57 (72) 50 (75) 47 (77) 0.003 18 (29) 23 (27) 21 (23) 17 (33) >0.9
1 n (%); Median (IQR)
2 Pearson’s Chi-squared test; Fisher’s exact test; Kruskal-Wallis rank sum test